Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avacta Group PLC (GB:AVCT)
LSE:AVCT
Holding GB:AVCT?
Track your performance easily
Earnings Data
Report Date
Apr 17, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 09, 2019
|% Change Since: -7.77%
|Next Earnings Date:Oct 02, 2018
Earnings Call Sentiment|Neutral
The earnings call presents a mixed picture, with positive strides in clinical trials and financial improvements in the diagnostics division, but challenges in securing licensing deals and funding persist. The exploration of a dual listing and ongoing trials offer potential upside, but uncertainty remains due to financial pressures and the need for more clinical data.Company Guidance
During the Avacta Group Plc investor call, CEO Christina Coughlin reported that the diagnostics division achieved an adjusted EBITDA of $0.1 million, recovering from a loss of $0.4 million in the first half of 2023, thanks to increased revenue and cost savings from relocating R&D activities. The call highlighted the investment in AVA6000, aiming to complete Phase 1a trials and prepare for Phase 2 development in 2025. The diagnostics division's operating activities generated a $1 million cash inflow, while the therapeutics division is expected to see increased cash outflows as trials progress. The company is exploring a sustainable funding strategy, including a potential dual listing on NASDAQ, as it transitions to focus solely on therapeutics.Diagnostics Division Achieves Positive EBITDA
The diagnostics division achieved an adjusted EBITDA of $0.1 million, an improvement from a loss of $0.4 million in the first half of 2023. This was driven by revenue growth and cost savings from facility consolidation.
AVA6000 Clinical Trial Progress
AVA6000 continues to show encouraging tolerability and efficacy signals in Phase 1a trials, with ongoing expansion cohorts to refine safety and efficacy in preparation for Phase 2.
Potential Dual Listing on NASDAQ
Avacta is exploring opportunities for a dual listing on NASDAQ as part of a sustainable long-term funding strategy.
Advancements in Precision Platform
The precision platform has shown promising preclinical results, with high tumor concentration of therapeutic agents and effective warhead delivery mechanisms.
Responses in Key Patient Populations
Multiple responses seen in patients with high-grade sarcomas and salivary gland cancers during AVA6000 trials, indicating potential effectiveness in these areas.
---
GB:AVCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:AVCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Sep 30, 2024 | 51.50p | 49.00p | -4.85% |
| Apr 30, 2024 | 48.30p | 45.75p | -5.28% |
| Sep 28, 2023 | 122.50p | 122.50p | 0.00% |
| Apr 25, 2023 | 130.50p | 127.20p | -2.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Avacta Group PLC (GB:AVCT) report earnings?
Avacta Group PLC (GB:AVCT) is schdueled to report earning on Apr 17, 2025, TBA Not Confirmed.
What is Avacta Group PLC (GB:AVCT) earnings time?
Avacta Group PLC (GB:AVCT) earnings time is at Apr 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Avacta Group PLC stock?
The P/E ratio of Avacta Group plc is N/A.
What is GB:AVCT EPS forecast?
Currently, no data Available
---